Neuphoria Therapeutics Inc

NEUP

4.010USD

+0.015+0.38%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Neuphoria Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

148 / 392

Overall Ranking

293 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Neuphoria Therapeutics Inc Highlights

StrengthsRisks

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Growing

The company is in a growing phase, with the latest annual income totaling USD 15.65M.

Overvalued

The company’s latest PE is -0.87, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.36M shares, decreasing 55.43% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 20.95K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.767

Target Price

+144.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Neuphoria Therapeutics Inc is 9.24, ranking 9 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.24

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.84

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Neuphoria Therapeutics Inc is 6.81, ranking 217 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.87, which is -7.24% below the recent high of -0.80 and -10049.29% above the recent low of -87.81.

Score

Industry at a Glance

Previous score

6.81

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 148/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Neuphoria Therapeutics Inc is 7.33, ranking 294 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 21.00 and a low of 2.30.

Score

Industry at a Glance

Previous score

7.33

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Neuphoria Therapeutics Inc is 2.88, ranking 370 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.21 and the support level at 3.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.30

Change

-0.42

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

875.33K

--

Baselake Management, LLC

222.22K

--

Robert (Eleanor Lipyanek)

173.72K

--

Shay Capital LLC

171.63K

--

Coastlands Capital LP

120.00K

--

Apeiron Investment Group Ltd

72.62K

-89.08%

AdvisorShares Investments, LLC

58.56K

-13.54%

Prosperity Wealth Management, Inc.

29.82K

+0.25%

Diadema Partners LP

21.45K

--

The Vanguard Group, Inc.

Star Investors

20.95K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neuphoria Therapeutics Inc is 1.18, ranking 342 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Neuphoria Therapeutics Inc

NEUP

5.99 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment